Search Results

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations

receptors would be a significant breakthrough in cardiovascular biology as they could be targeted for therapeutic

The dimer interface sits on helix 1, involves a domain-swapped N-terminus and helix 7, is twice the area

neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic

Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed

Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic

Terry Hebert is a Professor of Pharmacology and Therapeutics at McGill University. The goal is to test therapeutic strategies targeting the AT1R, alpha-adrenergic, and beta-adrenergic

Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic

Each session explores mechanistic models, translational challenges, and real-world therapeutic implications

Themes of the Conversation Allosteric modulation of opioid receptors - mechanism, selectivity, and therapeutic The therapeutic logic is that decoupling from the orthosteric site might preserve pain relief while altering

GPR56 as a mechanical sensor and his sustained case for the KLF2 signaling pathway as a GPCR-linked therapeutic His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

GPCR field, and serves as Deputy Director of the Australian Research Council Centre for Personalised Therapeutics Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics

company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics

. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes

modulate drug seeking, habit formation, and reward processing - and has been pursued as a potential therapeutic adolescent alcohol exposure disrupts mGlu2 function in the striatum in a way that might seem to close off therapeutic

Characterized by extracellular domains exceeding 1,000 amino acids, autoproteolytic cleavage at the membrane

By integrating advanced tools and translational biology, his work directly informs therapeutic strategies

Sep 20, 2022 — First contributor article published: Therapeutic validation of an orphan G protein‐coupled

Unconventional GPCR Ligands <p class="font_8">Watch Now</p> Terry Kenakin The New Frontier of GPCR Therapeutics

Clements' work is primarily focused on translational developments of small molecule therapeutics, and

analysis, revealed nuanced roles of RGS4, RGS9, and RGSZ — not just as modulators but as potential therapeutic

Each session explores mechanistic models, translational challenges, and real-world therapeutic implications

This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream

Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

The canonical assumption that targeting PLC would be therapeutic has failed in the clinic, and patients

structural biology and drug discovery, where molecular structures inform the design and development of new therapeutics You could easily imagine separate therapeutic programs targeting those different physiological effects

Later hepatotoxicity concerns and the success of antibody therapeutics further shifted strategy.